Omalizumab in children.

摘要: Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of circulating immunoglobulin E (IgE) and expression IgE high-affinity receptors on mast cells basophils, interrupting the subsequent allergic inflammatory cascade. Current indications for treatment with omalizumab in pediatric patients are clearly defined confined to moderate-to-severe uncontrolled asthma chronic spontaneous urticaria (CSU). Any other prescription can only be off label. Data available from clinical trials conducted children suggest clinically effective generally well tolerated. Given its mechanism action, recent reports have suggested possible use IgE-mediated disorders, such as rhinitis, food allergy, anaphylaxis. In years, several studies also investigated applications number non diseases. The aim present review assess all therapy population. approved indications—allergic CSU—are reviewed. Moreover, further potential discussed both non-IgE-mediated